Pre-announcement: CIHR HIV/AIDS Biomedical and Clinical Research Team Grants

The Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity (III) and the CIHR HIV/AIDS Research Initiative are pleased to announce the upcoming launch of a new Request for Applications (RFA) for HIV/AIDS Biomedical and Clinical Team Grants in May 2018.

Anticipated Timelines

  • Program launch: May 2018
  • Application deadline: November 2018

Description

The focused teams must involve a minimum of three investigators and may work in areas of higher risk.

The large teams, with a minimum of 8 investigators from at least three provinces or territories including at least one New Investigator and one mid-career investigator, will bring together experts from different disciplines working collaboratively on a number of inter-related research projects under a unified program of research.

To ensure teams are well positioned not only to generate important new knowledge but to also apply it in timely fashion, programs must include a strong core of basic scientists and clinical investigators. These teams must discuss training plans in order to build further capacity for HIV research and stimulate innovative approaches. They must also consider the relevance of their work to people living with HIV and its ethical implications and, therefore, must include relevant stakeholders in the oversight of the program of research.

Funds available

  • The total amount available for this funding opportunity is $20,000,000, enough to fund approximately 6 grants. This amount may increase if additional funding partners participate.
  • Of this $20M:
    • $8M is available for team grants, enough to fund 4 grants (2 “From Control to Cure” and 2 “Biomedical Prevention”).
    • $12M is available for large team grants, enough to fund 2 grants (1 “From Control to Cure” and 1 “Biomedical Prevention”).
  • For focused teams the maximum amount per grant is $400,000 per year for up to five years for the team grants.
  • For the large teams the maximum amount per grant is $1,200,000 per year for up to five years for the large team grants.

Objectives

The Team Grant HIV/AIDS Biomedical and Clinical Research is expected to contribute to the global search for a safe and effective cure for HIV, and to develop prevention strategies and tools.

The specific objectives of this funding opportunity are to:

  • transform HIV biomedical and clinical research in Canada into a collaborative, interdisciplinary model of knowledge creation and application through the funding of innovative research programs;
  • create an inclusive and sustainable pipeline of HIV research capacity from across disciplines, sectors, and perspectives (e.g., HIV basic scientists, clinical investigators, knowledge users and/or community members (people living with HIV));
  • effectively translate knowledge into clinical and/or commercial applications which contribute to the design, development and evaluation of research strategies; and
  • create a critical mass of technical and scientific expertise in Canada that engages meaningfully with one another, relevant national stakeholders and international research efforts.

Research areas

This funding opportunity will support projects relevant to the following research areas. It is not expected that programs will address all of the priority areas listed below, but rather, that they will target one of the following two priority areas.

  • From control to cure
    • Molecular, cellular, immunological and viral mechanisms to HIV persistence and latency
    • Immune based therapies to clear HIV
    • Develop and exploit cell or gene therapy for HIV Cure
    • Biomarkers identification, development and validation for HIV persistence
    • Research and development of latency reversing agents
    • Cellular and animal models of HIV latency
    • Analysis of viral reservoir when on antiretroviral therapy (ART)
  • Biomedical prevention
    • Immune based strategies to HIV prevention (can target any of the following : mucosal, innate, humoral or cellular immunity; immune correlates of prevention)
    • Preventive Vaccines, novel adjuvants, and new technologies to expedite vaccine development
    • Microbicides
    • Microbiome based HIV prevention strategies
    • HIV medication to prevent transmission (treatment as prevention; pre- and post-exposure prophylaxis)
    • Biomedical and clinical interventions  and evaluations of preventive strategies

To learn more

The complete RFA will be posted on ResearchNet by the end of May 2018.

Contact information

CIHR Contact Centre at 613-954-1968 or support-soutien@cihr-irsc.gc.ca.

Date modified: